Hasil Pencarian - David G Warnock

  • Menampilkan 1 - 10 hasil dari 10
Perbaiki Hasil
  1. 1
    Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease

    Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease oleh Fernando C Fervenza, Roser Torra, David G Warnock

    Diterbitkan 2008-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Current and Investigational Therapeutics for Fabry Disease

    Current and Investigational Therapeutics for Fabry Disease oleh Andrew Felis, Michael Whitlow, Abigayle Kraus, David G. Warnock, Eric Wallace

    Diterbitkan 2020-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study

    Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study oleh Christoph Wanner, Virginia Kimonis, Juan Politei, David G. Warnock, Nurcan Üçeyler, Aline Frey, Peter Cornelisse, Derralyn Hughes

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease.

    Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease. oleh Aurelie Nguyen Dinh Cat, Brigitte Escoubet, Vincent Agrapart, Violaine Griol-Charhbili, Trenton Schoeb, Wenguang Feng, Edgar Jaimes, David G Warnock, Frederic Jaisser

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    High-sensitivity C-reactive protein and risk of sepsis.

    High-sensitivity C-reactive protein and risk of sepsis. oleh Henry E Wang, Nathan I Shapiro, Monika M Safford, Russell Griffin, Suzanne Judd, Joel B Rodgers, David G Warnock, Mary Cushman, George Howard

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.

    Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy. oleh Sachie Nakano, Takahiro Tsukimura, Tadayasu Togawa, Toya Ohashi, Masahisa Kobayashi, Katsuyoshi Takayama, Yukuharu Kobayashi, Hiroshi Abiko, Masatsugu Satou, Tohru Nakahata, David G Warnock, Hitoshi Sakuraba, Futoshi Shibasaki

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm

    A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm oleh John L. Jefferies, Alison K. Spencer, Heather A. Lau, Matthew W. Nelson, Joseph D. Giuliano, Joseph W. Zabinski, Costas Boussios, Gary Curhan, Richard E. Gliklich, David G. Warnock

    Diterbitkan 2021-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy.

    A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy. oleh Andreas D Kistler, Justyna Siwy, Frank Breunig, Praveen Jeevaratnam, Alexander Scherl, William Mullen, David G Warnock, Christoph Wanner, Derralynn A Hughes, Harald Mischak, Rudolf P Wüthrich, Andreas L Serra

    Diterbitkan 2011-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Chronic Kidney Disease: A Public Health Problem That Needs a Public Health Action Plan

    Chronic Kidney Disease: A Public Health Problem That Needs a Public Health Action Plan oleh Anton C. Schoolwerth, MD, MSHA, Michael M. Engelgau, MD, Thomas H. Hostetter, MD, Kathy H. Rufo, MPH, Dolph Chianchiano, JD, MPA, William M. McClellan, MD, MPH, David G. Warnock, MD, Frank Vinicor, MD

    Diterbitkan 2006-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.

    Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase. oleh David G Warnock, Daniel G Bichet, Myrl Holida, Ozlem Goker-Alpan, Kathy Nicholls, Mark Thomas, Francois Eyskens, Suma Shankar, Mathews Adera, Sheela Sitaraman, Richie Khanna, John J Flanagan, Brandon A Wustman, Jay Barth, Carrolee Barlow, Kenneth J Valenzano, David J Lockhart, Pol Boudes, Franklin K Johnson

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: